• Aliases: CAL-101, GS-1101
    • An orally bioavailable, small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I PI3K that inhibits the production of the second messenger PIP3, preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival
    • FDA approved for relapsed CLL, follicular B-Cell NHL, and relapsed small lymphocytic lymphoma
    • Recommended dose: 150 mg twice daily regardless of food
    • Metabolism: Major CYP3A4 substrate
    • Half-life: â™8 hours
    • Common side effects: Fatigue, headache, skin rash, pneumonitis, myelosuppression, transaminitis, infection, diarrhea, abdominal pain, nausea/vomiting
    Other topics in Targeted and Immunotherapy Agents